Gland Pharma Share Price: Aaj toh 52-Week High ka record tod diya! Margin badhane se stock bhaga

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Gland Pharma Share Price: Aaj toh 52-Week High ka record tod diya! Margin badhane se stock bhaga
Overview

Arre, Gland Pharma ka stock aaj toh ekdum se bhaag gaya! Seedha **14.67%** upar chadha aur **₹2,142.30** ke 52-week high par pahunch gaya. Peeche ka reason? Company ka Q4 FY26 ka result ekdum zabardast aaya hai, jisme profit mein **96.56%** ka jump hai aur margins bhi kaafi badhe hain.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Margin Gains Fuel Gland Pharma's Rally

Toofani tezi ke peeche ka funda ye hai ki company ke results bahut hi shaandaar aaye hain. Q4 FY26 mein, Gland Pharma ne ₹366.67 crore ka consolidated profit reported kiya hai, jo pichle saal ke ₹186.54 crore se lagbhag double yaani 96.56% zyada hai. Revenue bhi 22.3% badh kar ₹1,742.79 crore ho gaya. Company keh rahi hai ki ye badhotri capacity badhane aur naye products launch karne ki wajah se hui hai.

Sabse mast baat ye hai ki inka EBITDA margin 24% se badh kar 29% ho gaya hai. Iss badhotri ke pichhe hai costs control karna, operating leverage ka fayda uthana, aur strategic contract renegotiations. Is wajah se EBITDA 48% badh kar ₹513 crore ho gaya.

Waise, ye CDMO (Contract Development & Manufacturing Organization) segment is quarter mein company ka hero raha. Isne total revenue ka 46% contribute kiya aur 36% growth dikhaya. Baaki base business ne bhi 38% ka adjusted EBITDA margin show kiya.

Competitive Position and Valuation

Stock ka market cap filhaal ₹35,255.72 crore ke aas paas hai. Analyst logon ko lagta hai ki valuation abhi bhi attractive hai, khaas kar ke jab ye complex injectables aur CDMO services mein focus kar rahe hain. Inka TTM P/E ratio 26.31 se 36.33 ke beech hai.

Market Context and Past Performance

Mazedaaar baat ye hai ki jab pure market mein Sensex aur Nifty gire hue the, tab bhi Gland Pharma ka stock 14.67% bhaaga aur ₹2,142.30 ke 52-week high par pahunch gaya. Ye ek solid comeback hai Q4 FY25 ke comparison mein jab profit gira tha.

Potential Risks to Monitor

Abhi bhi kuch cheezein hain jin par nazar rakhni hogi, jaise Cenexi jaise acquired companies ko integrate karna, naye products launch karne mein success, aur US market mein pricing pressures ya regulatory issues.

Analyst Views and Outlook

Lekin overall, analysts bahut positive hain. Motilal Oswal Financial Services ne ₹2,300 ka target diya hai, Elara Capital ne ₹2,306, aur Jefferies ne ₹2,080. Company ne FY26 ke liye ₹20 per share ka dividend bhi propose kiya hai jo shareholders ke liye achhi khabar hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.